Fast Five Quiz: Management of Metastatic Bladder Cancer

Kyle A. Richards, MD


March 24, 2022

For medically fit patients with metastatic bladder cancer, cisplatin-based combination chemotherapy is the standard of care for first-line treatment. The most common systemic regimens include methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), either classic or dose-dense MVAC regimens, and doublet therapy with cisplatin and gemcitabine. With cisplatin-based combination chemotherapy, the median progression-free survival is 7 months and median overall survival is 15 months. Although bladder cancer is chemotherapy-sensitive, the risk for recurrence is estimated to be 100%.

Compared with single-agent cisplatin therapy, MVAC has demonstrated improved overall response rates, median progression-free survival, and median overall survival, according to Loehrer Sr and colleagues.

Intravesical chemotherapy may be an option for early-stage localized bladder cancers.

Radical cystectomy may be an option for localized muscle-invasive bladder cancer after neoadjuvant chemotherapy.

Learn more about metastatic bladder cancer management.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.